BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript

BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript March 27, 2024

BioCardia, Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.11. BCDA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the BioCardia 2023 Year-End Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions]. Participants on this call are advised that the audio of this conference call is being broadcast live over the Internet and is also being recorded for playback purposes. A webcast replay of the call will be available approximately one hour after the end of the call. I would now like to turn the call over to Miranda Peto, BioCardia Investor Relations. Please go ahead, Miranda.

Miranda Peto: Thank you, Rocco. Good afternoon and thank you for participating in today’s conference call. Joining me from BioCardia’s leadership team are Peter Altman, PhD, President and Chief Executive Officer and David McClung, the company’s Chief Financial Officer. During this call, management will be making forward-looking statements, including statements that address BioCardia’s expectations for future performance and operational results, references to management’s intentions, beliefs, projections, outlook, analyses and current expectations. Such factors include, among others, the inherent uncertainties associated with developing new products, technologies and obtaining regulatory approvals. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements.

For more information about these risks, please refer to the risk factors and cautionary statements described in BioCardia’s report on Form 10-K filed with the SEC this morning. The content of this call contains time-sensitive information that is accurate only as of today, March 27, 2024. Except as required by law, the company disclaims any obligation to publicly update or revise any information to reflect events or circumstances that events occur after this call. It is now my pleasure to turn the call over to Peter Altman, PhD, BioCardia’s President and CEO. Peter, please go ahead.

Peter Altman: Thank you, Miranda, and good afternoon to everyone on the call. BioCardia’s current efforts are focused on advancing its autologous and its allogeneic cell therapy platforms to treat significant unmet cardiovascular diseases, specifically ischemic heart failure and chronic myocardial ischemia. All of our cell-based therapies involve local delivery of the therapeutic to the heart or lungs, where we intend them to act locally. Our lead CardiAMP autologous cell therapy is targeted to treat ischemic heart failure of reduced ejection fraction. Today, heart failure of reduced ejection fraction remains a significant unmet clinical need as none of the recently approved therapies reduce mortality, which remains at approximately 10% per year.

To put this into context, it has been reported that heart failure is as malignant as some common cancers. Men with heart failure have a worse five-year survival than do men with either prostate or bladder cancer. Women with heart failure have been shown to have a worse five-year survival than women with breast cancer. Heart failure also impacts more than 5 million patients in the United States and is growing. In our lead CardiAMP cell therapy, the patient has cells taken from their bone marrow, processed at point of care in our disposable cell processing kit and delivered to our minimally invasive catheter system to tend targeted regions around damage in the heart. We now have three clinical trials in the treatment for heart failure with the CardiAMP cell therapy that lend support for both safety and therapeutic efficacy for patients having ischemic heart failure of reduced ejection fraction.

Our recent experience in missing the primary pre-specified endpoint in our cardiac heart failure clinical trial, while not our chosen path, is not a unique experience for those developing therapies for this disease. Our world-class executive steering committee and the distinguished cardiologists on our data safety monitoring board see that the results just presented from the CardiAMP heart failure trial are compelling, as evidenced by our investigators and our Data Safety Monitoring Board continuing to support and be involved in the program. The interim data presentation from the cardiac heart failure trial presented scientifically earlier this month shows 37% relative risk reduction in heart death equivalents, 9.2% relative risk reduction in non-fatal major adverse cardiac and cerebrovascular events, reduced cardiac arrhythmias, and enhanced heart function in treated patients relative to the control patients.

In addition, the available interim data showed that for an important subset of patients who presented at the screening baseline visit with higher levels of NT-proBNP, a well-established biomarker of active heart failure and stress to the heart, the reduction in heart death equivalents were even greater. Of note, all current leading heart failure trials where we have looked require elevated NT-proBNP for patients to be eligible to participate in these trials. In these patients, an analysis of all available data up to two years in the cardiac heart failure trial with a mean of 20 months follow-up shows improvements over controls, including an 86% relative risk reduction in mortality and a 24% relative risk reduction of non-fatal major adverse cardiac and cerebrovascular events.

Further, all clinical outcomes included in this subset analysis, favorite cell therapy including improved quality of life as measured using the Minnesota Living with Heart Failure questionnaire, reduction of NT-proBNP levels, greater six-minute walk test distance and improved echocardiography parameters of left ventricular ejection fraction, left ventricular and systolic volume, and left ventricular and diastolic volume. Both the reduced heart death equivalents and improved quality of life outcomes demonstrate statistical significance favoring therapy in this subset analysis. This is the subgroup we have designed CardiAMP catheter to inflammatory trial around, which is approved by FDA in December activated in February and approved reimbursement Medicare in March.

We continue to monitor patients enrolled in the CardiAMP heart failure clinical study in which both patients and evaluating physicians are blinded to the treatment group and we expect to complete follow-up in this study in October 2024. As we already have more than 90% of the patient follow-up data that we will ultimately have in the final analysis, we don’t expect the results to change significantly. This final data on the patients already treated is expected to be provided to Japan’s Pharmaceutical and Medical Device Agency toward approval for the indication of ischemic heart failure. Our formal consultation in November 2023 has suggested that if the data remains as good as it currently appears to be at the final analysis, they are inclined to support approval based on this data without requiring a trial in Japan.

Subsequent interactions and consultations with Japan’s pharmaceutical and medical device agencies are expected. The confirmatory, CardiAMP heart failure II study approved by FDA in December 2023 is a Phase 3 multicenter, randomized, double-blind controlled study of up to 250 patients with NT-proBNP levels greater than 500 pg/ml at up to 40 centers in the United States. The primary endpoint is an outcomes composite score based on a three-tiered Finkelstein Schoenfeld Hierarchical Analysis. The tiers starting with the most serious events would be Tier 1 all cause death, including cardiac death equivalents such as heart transplant or left ventricular assist device placement ordered by time to event. Tier 2, non-fatal major adverse coronary and cerebrovascular events.

And Tier 3, change from baseline and quality of life at a minimum of 12 months and a maximum of 24 months. The trial as designed has a greater than 90% power or statistical probability of success to meet the primary endpoint based on the cardiac heart failure trial interim results. We are actively working with our heart failure network and leaders in cardiology to enroll and complete this study as soon as possible. We expect additional news throughout the year on this study. Our CardiAMP cell therapy trial for chronic myocardial ischemia or BCDA-02 is a Phase 3 multicenter randomized double-blinded controlled study intended to include up to 343 patients at up to 40 clinical sites. The company expects to complete enrollment in the rolling cohort soon and begin the randomized phase of the trial.

A number of leading investigators including both principal investigators in this trial believe this to be the most compelling indication for the CardiAMP autologous cell therapy. Planning for the randomization phase continues based on promising experience in the patients treated to date. Part of this planning includes utilizing the Medicare reimbursement in place for both the control and treatment arms of this investigational therapeutic study to offset the clinical costs. The company’s CardiALLO allogeneic cell therapy for ischemic heart failure or BCDA-03 is a Phase 1/2 clinical program encompassing 69 patients. We have reported first patient enrolled in the fourth quarter of 2024, the Technology and Heart Failure Therapeutics meeting earlier this month, it was also reported that there have been no adverse events in follow-up.

The CardiALLO heart failure study is intended to build on three previous trials of mesenchymal stem cells in ischemic heart failure using the company’s proprietary Helix Delivery System, encompassing 93 patients treated with no treatment-emergent serious adverse events and compelling early signals for benefit. This is a precision medicine study as we are focusing this therapy for the first times on patients who have elevated NT-proBNP and elevated high sensitivity C reactive protein, a marker of inflammation that has been reported for patients with heart failure most responsive to immunomodulatory mesenchymal stem cells. Our strategy to advance our CardiALLO allogeneic program is to seek partnerships and grant funding as it will not have the benefit of Medicare reimbursement in the United States.

We intend the Phase 2 portion of the study to be performed in both the United States and in Japan where it has potential to receive conditional approval based on this one trial. In 2023, we evolved our Helix Biotherapeutic Delivery Partnering Business to focus on long-term partnerships where BioCardia shareholders participate meaningfully in the value created. Our Helix transendocardial delivery system is a therapeutic enabling platform for minimally invasive targeted delivery of biologic agents to the heart. This platform enables all of our therapeutic development efforts and it empowers a seamless transition from bench to commercialization for partners. Our biotherapeutic delivery partnerships are expected to enhance future treatment options for millions of patients suffering from heart disease, offset the cost of biotherapeutic delivery for our own therapeutic programs and provide our shareholders with meaningful revenue sharing should our partnering efforts contribute to successful therapeutic development.

In September 2023, our biotherapeutic delivery partner CellProthera announced completion of enrollment in their Phase 1/2 cell therapy study and post myocardial infarction and results are expected soon. In March of 2024, we announced a biotherapeutic delivery partnership with StemCardia for a long-term partnership to advance StemCardia’s investigational pluripotent stem cell product candidate for the treatment of heart failure initially through a Phase 1/2 clinical study. Two additional premier biotherapeutic delivery partnerships are expected in 2024. Our Morph Access Innovations business is based on the steerable catheter systems through which we perform all of our Helix procedures for biotherapeutic intervention. We are working to obtain FDA approval in Q3 2024 for a product family of Morph DNA steerable sheath introducers in a variety of sizes and lengths with clinical indications for use in the heart and peripheral vascular.

BioCardia is actively exploring pathways for commercializing these products in the second half of the year. In summary, we have increased confidence in the potential of our autologous CardiAMP cell therapy program in both ischemic heart failure and in chronic myocardial ischemia based on the data we have before us. We are focused strategically on advancing these 2 clinical programs in a cash neutral fashion with the benefit of the Medicare reimbursement we already have in place. Similarly, we are working on securing grants and partnerships around our allogeneic programs to support their continued clinical development and implementing a recurring revenue biotherapeutic delivery partnering model that includes revenue sharing with our experienced world-class team and our Helix biotherapeutic delivery system.

In the coming weeks, we anticipate enrollment of patients in our CardiAMP heart failure two confirmatory study and we will be working on a number of business development activities which have potential to be impactful in our plans for staying listed on NASDAQ. I will now pass the call to David McClung, our CFO, who will review our Q3, Q4 2023 financial results.

David McClung: Thank you, Peter, and good afternoon, everyone. Revenues were $0.5 million in 2023 compared to $1.4 million in 2022, primarily due to the timing of revenue earned from new and existing collaborative partners, coupled with the fulfillment of performance obligations in 2022. Expenses year-over-year decreased by 9%. Research and development expenses decreased to $7.7 million in 2023 compared to $8.8 million in 2022, primarily due to the completion of enrollment in the Cardiac Heart Failure trial, coupled with reduced expenses in clinical and related supporting functions. Selling, general and administrative expenses were unchanged at $4.4 million in both 2023 and in 2022. Our net loss in 2023 was $11.6 million, compared to $11.9 million in 2022.

We used $10 million in cash for operations in 2023, compared to $10.6 million in 2022. And BioCardia ended the year with $1.1 million in cash and cash equivalents, which together with financing proceeds in the first quarter of 2024 provide runway into the second quarter of 2024. As disclosed in our recent SEC filings, the company has received a determination letter from NASDAQ advising us that the company is not in compliance with listening standards and is subject to delisting. BioCardia intends to remain listed in NASDAQ Capital Markets. Accordingly, BioCardia’s appealing the decision has requested a hearing where the company will submit its plan to regain compliance. The appeal has a state suspension of the company securities pending the hearing.

This concludes management’s prepared comments and we’re happy to take questions from attendees.

See also 20 Largest Airport Companies in the World by Market Cap and 15 Best Tequila Brands at Costco and Sam’s Club.

Q&A Session

Operator: Thank you. [Operator Instructions]. And today’s first question comes from Joe Smith at Alpha Street. Please go ahead. Hello, Mr. Smith. Your line is open, sir. And it appears we lost Mr. Smith’s connection. Our next question today comes from Brent Pearson, a Private Investor. Please go ahead.

Unidentified Analyst: Good afternoon, gentlemen. I saw that in Q4 you filed a $50 million prospectus. Is that planned to get funding through your BCDA-01 and 02 trials for the next few years? Is part of that to be put into a ramp-up if devices get approved or if you get approval in Japan and you need to ramp up production? Could you give us any commentary that would help us understand the intention for that $50 million?

Peter Altman: You want to take David?

David McClung: Well, this is, we have our S3 we had on file that expired in October. This is simply just refreshing our S3 again. So, we have another one on file. It’s a typical resource that we want to have available to us, we’ll use for ATMs and other things as we need.

Unidentified Analyst: So, it’s more along the lines of bumping along an existing prospectus that you want to keep open. In terms of your capital needs throughout the rest of the year, I assume you’re going to look at the market financings as things are come apparent and I assume that you don’t expect to have a much different capital usage than you had through 2023. Is that something that we can count on?

Peter Altman: Joe, these are great questions and as where we are right now, this is actually, this is sort of the eye of the storm. Our ongoing business development activities as we’ve shared, interweave with this and so we are proceeding with really all options on the table and things will evolve in the coming months as we have our discussions with NASDAQ. So, I think that’s probably the best way to describe it. As far as your second follow-up question, our cash needs, I would actually say that our cash needs today are modest. We have publicly disclosed that our burn rate has been significantly reduced as we turn down the spend on the clinical trial that we’re now doing follow-up on. The spend could go back up as we accelerate in the cardiac heart failure II to be closer to what it was last year and the variety of partnerships that are coming together could actually result in non-dilutive reduction in our burn rate.

So, these are the forces that are playing here right now. I don’t expect a significant increase in the burn rate, even if we had no revenues, primarily because of the Medicare reimbursement and the stage of the third program still in the Phase 1 dose escalation phase which is more limited. But we are seeking significantly non-dilutive financing for that. And Brent, forgive me, I referred to you as Joe earlier. My apologies.

Unidentified Analyst: No worries. I appreciate the color there. I guess my last question was, we had seen that there were some partner developments mentioned in Q2 and Q3. Does the horizon look about the same? Is there any color that you can provide on that front?

Peter Altman: Yes. So, I did share that we expect to have two additional biotherapeutic partnerships this year and I even believe we have one targeted to be completed this next quarter. But I’d have you think about it in this fashion. When we do work with a partner, oftentimes we create a very significant data set that takes a period of a year or 02 to develop and then they think about how to take that forward into the clinic or they are in a clinic already and they think about how to take that to the next stage of development. And so, each time we partner, we receive revenues, but the amount of resources being spent on the program is far more significant by our partners. One of the things that we’re choosing to do is we’re focused completely on long-term partnerships.

We do not sell delivery systems. We partner. And that means that if there is value created from the collaboration, then we meaning the BioCardia shareholders will ultimately benefit from that even if BioCardia does not actually wind up commercializing alongside our partners in the future, which if we do, the value for our shareholders would be quite significant. And that’s really our goal at the end of the day, but we don’t if we’re going to do the work with a partner, enable them access to our technology and knowhow and experienced team, we not only need to get paid for the work we do along the way and the products we provide, but the value creation on the therapeutic side, we also need to participate in. And so that’s a new structure that we’re having going forward.

And it makes sense. It doesn’t cause it’s a little different, but it doesn’t cause anyone any undue concerns.

Operator: And our next question today comes from George [indiscernible] with no company given. Please go ahead.

Unidentified Analyst: Thank you, for taking my questions. Peter, I just had actually you just answered most of the you just provided most of the information I have regarding partnerships. But I guess it looks like you picked up an additional partner this year per the press release this afternoon. There were two at the end of last year and it looks like you have and then in the press release, stem cardio came out, but then you have two additional partners, chips that are lined up for this year. Is that accurate?